COVID-19所致低氧性呼吸衰竭患者的清醒俯卧位:PROFLO多中心随机临床试验
PROFLO为多中心随机临床试验,纳入需高流量鼻导管氧疗或无创通气、PaO2/FiO2≤20 kPa的成人COVID-19确诊患者,随机分为以每日16小时为目标的清醒俯卧位方案组或标准治疗组,主要终点为30天内插管。因无效提前终止,共75例随机(对照组39例、俯卧位组36例)。30天内插管率对照组13例(33%)与俯卧位组12例(33%)无差异(HR 1.01,95%CI 0.46-2.21,P=0.99);俯卧位组每日俯卧位时间中位数9.0小时(IQR 4.4-10.6)高于对照组3.4小时(IQR 1.8-8.4)(P=0.014)。结论:该方案未降低插管率。
要点
- 30天内插管率:对照组13例(33%)vs 俯卧位组12例(33%),HR 1.01(95%CI 0.46-2.21),P=0.99,无差异。
- 实际俯卧位时长:对照组中位3.4小时/日(IQR 1.8-8.4)vs 俯卧位组9.0小时/日(IQR 4.4-10.6),P=0.014。
- 压疮:对照组9例(23%)vs 俯卧位组2例(6%),差值-18%(95%CI -2至-33%),P=0.032。
- 30天死亡率、无呼吸机天数、住院及ICU住院时长、无创通气使用、器官支持及其他不良事件两组无其他差异。
- 试验因无效提前终止,共随机75例(对照组39例、俯卧位组36例)。
适用人群与场景
- 确诊COVID-19的成人患者,因呼吸支持使用高流量鼻导管氧疗或无创通气,且PaO2/FiO2≤20 kPa。
诊断标准与关键阈值
- 纳入标准:确诊COVID-19、使用高流量鼻导管氧疗或无创通气、PaO2/FiO2≤20 kPa的成人患者。
处置流程与药物剂量
- 干预组采用以每日16小时俯卧位为目标的清醒俯卧位方案,对照组接受标准治疗。
研究设计与关键结果
- 多中心随机临床试验,141例评估合格,75例随机(对照组39例、俯卧位组36例),因无效提前终止。
- 主要终点30天内插管:对照组13例(33%)vs 俯卧位组12例(33%),HR 1.01(95%CI 0.46-2.21),P=0.99。
- 每日俯卧位时间中位数:对照组3.4小时(IQR 1.8-8.4)vs 俯卧位组9.0小时(IQR 4.4-10.6),P=0.014。
- 压疮:对照组9例(23%)vs 俯卧位组2例(6%),差值-18%(95%CI -2至-33%),P=0.032。
- 30天死亡率、无呼吸机天数、住院及ICU住院时长、无创通气使用、器官支持及其他不良事件两组无其他差异。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 试验因无效提前终止。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该清醒俯卧位方案虽延长了俯卧位时间,但未降低COVID-19中重度低氧性呼吸衰竭患者的插管率;作者结论为该方案与标准治疗相比未减少插管。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of awake prone positioning on intubation rates is not established. The aim of this trial was to investigate if a protocol for awake prone positioning reduces the rate of endotracheal intubation compared with standard care among patients with moderate to severe hypoxemic respiratory failure due to COVID-19.
METHODS: We conducted a multicenter randomized clinical trial. Adult patients with confirmed COVID-19, high-flow nasal oxygen or noninvasive ventilation for respiratory support and a PaO2/FiO2 ratio ≤ 20 kPa were randomly assigned to a protocol targeting 16 h prone positioning per day or standard care. The primary endpoint was intubation within 30 days. Secondary endpoints included duration of awake prone positioning, 30-day mortality, ventilator-free days, hospital and intensive care unit length of stay, use of noninvasive ventilation, organ support and adverse events. The trial was terminated early due to futility.
RESULTS: Of 141 patients assessed for eligibility, 75 were randomized of whom 39 were allocated to the control group and 36 to the prone group. Within 30 days after enrollment, 13 patients (33%) were intubated in the control group versus 12 patients (33%) in the prone group (HR 1.01 (95% CI 0.46-2.21), P = 0.99). Median prone duration was 3.4 h [IQR 1.8-8.4] in the control group compared with 9.0 h per day [IQR 4.4-10.6] in the prone group (P = 0.014). Nine patients (23%) in the control group had pressure sores compared with two patients (6%) in the prone group (difference - 18% (95% CI - 2 to - 33%); P = 0.032). There were no other differences in secondary outcomes between groups.
CONCLUSIONS: The implemented protocol for awake prone positioning increased duration of prone positioning, but did not reduce the rate of intubation in patients with hypoxemic respiratory failure due to COVID-19 compared to standard care.
TRIAL REGISTRATION: ISRCTN54917435. Registered 15 June 2020 ( https://doi.org/10.1186/ISRCTN54917435 ).
参考来源
- Rosén J, von Oelreich E, Fors D, et al. Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial. Crit Care. 2021. PMID: 34127046. doi:10.1186/s13054-021-03602-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。